Login to Your Account

Amgen's Vectibix Misses Mark, But Data Inspire Some Optimism

By Catherine Hollingsworth

Friday, November 6, 2009
Although Amgen Inc.'s Phase III Vectibix-Folfox combination met its main goal - to improve progression-free survival in patients with advanced colorectal cancer in the first-line setting - it missed its secondary endpoint of overall survival, the company reported Thursday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription